WEST PALM BEACH, Fla. — Discontinuing disease-modifying therapies (DMTs) for multiple sclerosis (MS) after prolonged disease stability poses minimal risk for patients aged > 60 years, highlighting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback